Biohacking for Longevity: Implications for Cancer Research and Treatment

Abhishek Pathak

doi:10.25259/ICAJ_17_2024

View/Download PDF

Buy Reprints

PDF

Translate this page into:

Editorial

3 (

1

); 1-2

doi:

10.25259/ICAJ_17_2024

Biohacking for Longevity: Implications for Cancer Research and Treatment

Abhishek Pathak^1,

1Department of Medical Oncology, Command Hospital, Lucknow, Uttar Pradesh, India.

*Corresponding author: Abhishek Pathak, Department of Medical Oncology, Command Hospital, Lucknow, Uttar Pradesh, India. drabhipat@gmail.com

Received: 2024-07-04, Accepted: 2024-07-04, Published: 2024-07-25

Licence

This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-Share Alike 4.0 License, which allows others to remix, transform, and build upon the work non-commercially, as long as the author is credited and the new creations are licensed under the identical terms.

How to cite this article: Pathak A. Biohacking for Longevity: Implications for Cancer Research and Treatment. Indian Cancer Awareness J. 2024;3:1-2. doi: 10.25259/ICAJ_17_2024

In recent years, the concept of biohacking has emerged as a promising frontier in the pursuit of extending human lifespan. Defined broadly as the application of scientific knowledge and technology to manipulate biological processes, biohacking encompasses a spectrum of practices aimed at enhancing human health and longevity. From genetic modifications to personalised medicine, biohackers explore innovative ways to optimise the human body’s functioning, raising profound questions about ethics, regulation and potential benefits, especially in fields like oncology.

UNDERSTANDING BIOHACKING

Biohacking techniques designed to extend longevity include a range of interventions, each targeting different aspects of cellular ageing and disease prevention. At the forefront of this movement are advancements in gene editing technologies such as CRISPR/Cas9, which enable precise alterations to the genome to correct genetic defects or enhance resistance to diseases like cancer.^[1] Similarly, senolytics – a class of drugs that selectively eliminate senescent cells – hold promise in delaying age-related decline and potentially reducing cancer risk by clearing cells susceptible to malignant transformation.^[2]

BIOHACKING AND CANCER: POTENTIAL BENEFITS

The intersection of biohacking and oncology presents intriguing possibilities for cancer prevention and treatment. Genetic modifications through CRISPR/Cas9, for instance, could potentially enable researchers to address genetic mutations associated with increased cancer susceptibility, paving the way for personalised cancer prevention strategies.^[3] Moreover, advancements in personalised medicine allow for tailored approaches to cancer treatment, leveraging genomic information to optimise therapeutic outcomes and minimise side effects.^[4]

ETHICAL CONSIDERATIONS

Despite the promise of biohacking technologies, ethical considerations loom large. The prospect of genetically modifying humans raises profound ethical questions regarding safety, equity and consent. Concerns about unintended consequences, such as off-target effects of gene editing, underscore the need for rigorous regulatory oversight and transparent communication with the public.^[5] Balancing the potential benefits of biohacking with ethical imperatives is crucial to ensuring responsible innovation in this rapidly evolving field.

THE ROLE OF ONCOLOGY IN BIOHACKING

Oncologists are increasingly exploring the potential of biohacking technologies to enhance cancer research and treatment. Collaborations between biohackers and oncologists hold promise for accelerating discoveries in cancer biology, facilitating the development of novel therapies and improving patient outcomes. By harnessing biohacking techniques, researchers can gain deeper insights into cancer mechanisms and devise innovative approaches to overcoming treatment resistance and minimising recurrence.^[6]

CHALLENGES AND LIMITATIONS

Despite the excitement surrounding biohacking, significant challenges remain. Technical hurdles, such as delivery mechanisms for gene editing tools and the complexity of biological systems, pose formidable obstacles to widespread application.^[7] Moreover, the long-term safety and efficacy of biohacking interventions require rigorous scientific scrutiny and careful consideration of potential risks. Addressing these challenges will be essential for realising the full potential of biohacking in oncology and beyond.

FUTURE DIRECTIONS

Looking ahead, the future of biohacking in oncology holds promise for transformative advancements. Continued research into gene editing, senolytics and personalised medicine is poised to yield ground-breaking insights into cancer biology and therapeutic strategies. Collaborative efforts between biohackers, oncologists and regulatory bodies will be essential for navigating ethical complexities and translating scientific discoveries into safe, effective treatments.^[8]

CONCLUSION

Biohacking represents a paradigm shift in our approach to human health and longevity, offering unprecedented opportunities to combat age-related diseases such as cancer. As we navigate this frontier, it is imperative to uphold ethical principles, prioritise patient safety and foster interdisciplinary collaboration. By harnessing the potential of biohacking technologies responsibly, we can envision a future where innovative therapies empower individuals to live longer, healthier lives, free from the burden of cancer and other age-related ailments.

In conclusion, the convergence of biohacking and oncology presents a compelling narrative of scientific progress and ethical responsibility. By embracing this intersection, we can chart a course toward a future where longevity is not just a dream but a tangible reality grounded in rigorous science and compassionate care.

References

Doudna JA, Charpentier E. The New Frontier of Genome Engineering with CRISPR-Cas9. Science. 2014;346:1258096.
[CrossRef] [PubMed] [Google Scholar]
Xu M, Pirtskhalava T, Farr JN, Weigand BM, Palmer AK, Weivoda MM, et al. Senolytics Improve Physical Function and Increase Lifespan in Old Age. Nat Med. 2018;24:1246-56.
[CrossRef] [PubMed] [Google Scholar]
Cyranoski D. CRISPR Gene-editing Tested in a Person for the First Time. Nature. 2019;574:447-8.
[CrossRef] [PubMed] [Google Scholar]
Hampel H, Bennett RL, Buchanan A, Pearlman R, Wiesner GL, Guideline Development Group, et al. A Practice Guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: Referral Indications for Cancer Predisposition Assessment. Genet Med. 2020;22:861-7.
[Google Scholar]
Regalado A. Engineering the Perfect Baby. 2015. MIT Technology Review. Available from: https://www.technologyreview.com/s/535661/engineering-the-perfect-baby [Last accessed on 2024 Jun 28]
[Google Scholar]
Cho SW, Kim S, Kim JM, Kim JS. Targeted Genome Engineering in Human Cells with the Cas9 RNA-guided Endonuclease. Nat Biotechnol. 2021;31:230-2.
[CrossRef] [PubMed] [Google Scholar]
Barrangou R, Doudna JA. Applications of CRISPR Technologies in Research and Beyond. Nat Biotechnol. 2016;34:933-41.
[CrossRef] [PubMed] [Google Scholar]
National Academies of Sciences, Engineering, and Medicine. Human Genome Editing: Science, Ethics, and Governance United States: National Academies Press; 2017.
[Google Scholar]